Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT exon11||gastrointestinal stromal tumor||decreased response||Sunitinib||Clinical Study - Cohort||Actionable||In a retrospective analysis, GIST patients with KIT exon 11 mutations showed decreased benefit compared to patients with exon 9 mutations, with median PFS of 7.0 months with exon 11 mutations vs. 12.3 months with exon 9 mutations, and an ORR of 6% (9/143) vs. 19% (8/42) following treatment with Sutent (sunitinib) (PMID: 26772734).||26772734|